Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label dose optimization study of ABP-700 in healthy adults
NL-OMON42641Phase 1Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of moxetomidate in Not applicable, sponsored by The Medicines Company. Primary endpoints: Safety and tolerability of ABP-700 and Bolus dose optimization of ABP-700 with premedications. Started Apr 2015; status: active, not recruiting.
02
Drugs
moxetomidate
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON42641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42641.